Skip to main content

Table 1 Layout of central composite design batches (*average ± SD, n = 3)

From: An impact of nanocrystals on dissolution rate of Lercanidipine: Supersaturation and crystallization by addition of solvent to antisolvent

Run

X1 (Conc of PVP, %w/v)

X2 (SAS Ratio)

Y1 (Particle size, nm)*

Y2 (%CDR10)*

CCD1

0

0

311.00 ± 4.00

87.39 ± 3.89

CCD2

+ 1.41

0

352.67 ± 3.79

79.71 ± 4.84

CCD3

− 1.41

0

414.67 ± 6.03

67.65 ± 5.95

CCD4

+ 1

+ 1

324.67 ± 6.51

84.98 ± 4.62

CCD5

0

+ 1.41

302.00 ± 10.58

88.95 ± 4.99

CCD6

− 1

− 1

464.33 ± 5.51

58.41 ± 5.07

CCD7

0

− 1.41

484.33 ± 6.51

56.29 ± 4.79

CCD8

+ 1

− 1

383.67 ± 6.51

72.97 ± 4.60

CCD9

− 1

+ 1

341.33 ± 4.16

83.59 ± 4.56

LER NCs

0.56

27

308.18 ± 10.56

87.50 ± 1.17

Independent variables

Levels

− α(− 1.41)

− 1

0

+ 1

+ α(+ 1.41)

X1 = Concentration of PVP

0.15

0.25

0.5

0.75

0.85

X2 = SAS ratio

6

10

20

30

34